SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

• Published in: Leukemia Vol. 26; no. 8; pp. 1892 - 1895
• Main Authors: Cao, Z-X, Liu, J-J, Zheng, R-L, Yang, J, Zhong, L, Xu, Y, Wang, L-J, Zhang, C-H, Wang, B-L, Ma, S, Wang, Z-R, Xie, H-Z, Wei, Y-Q, Yang, S-Y
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2012; Nature Publishing Group
• Subjects: 631/154/436/1729; 631/67/1059/99; 692/699/67/1990/283/1896; 692/699/67/1990/283/1897; Animals; Antibodies; Biological and medical sciences; Cancer; Cancer Research; Care and treatment; Cell cycle; Cell Line, Tumor; Cell Proliferation - drug effects; Critical Care Medicine; fms-Like Tyrosine Kinase 3 - antagonists & inhibitors; fms-Like Tyrosine Kinase 3 - genetics; fms-Like Tyrosine Kinase 3 - metabolism; Gene expression; Gene mutations; Genetic aspects; Hematologic and hematopoietic diseases; Hematology; Humans; Inhibitory Concentration 50; Intensive; Internal Medicine; Kinases; letter-to-the-editor; Letters to the editor; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical prognosis; Medical sciences; Medicine; Medicine & Public Health; Mutation; Oncology; Phosphorylation; Phosphorylation - drug effects; Physiological aspects; Prognosis; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacology; Protein kinases; Proteins; Proto-Oncogene Proteins c-abl - antagonists & inhibitors; Proto-Oncogene Proteins c-abl - genetics; Proto-Oncogene Proteins c-abl - metabolism; Purines - pharmacology; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Stem cells; Xenograft Model Antitumor Assays; Acute myelogenous leukemia; Anti-EGFR; Hematology; FLT3 gene; Chronic myelogenous leukemia; Malignant hemopathy; trk receptor; Biological activity; Myeloproliferative syndrome; C-Onc gene; Models; Multikinase inhibitor; Mutation; Protooncogene; Cancer
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2012.67